<p>阿玛琳公司（NASDAQ:AMRN - 获取免费报告）在周五的交易中达到了新的 52 周低点。该股最低交易价格为 0.44 美元，最后交易价格为 9.11 美元，成交量为 1319852 股。该股此前收盘价为 0.46 美元。</p>
<h2>分析师设定新的价格目标</h2>
<ul>
<li>3 只生物技术股票正在获得动力</li>
</ul>
<p>另外，StockNews.com 在周二开始对阿玛琳的股票进行覆盖。他们对该股给予了 “卖出” 评级。</p>
<p><strong>查看我们关于 AMRN 的最新研究报告</strong></p>
<h2>阿玛琳股票表现</h2>
<ul>
<li>Ocugen 或阿玛琳是否值得投资的便士股票？</li>
</ul>
<p>该公司的 50 日移动平均价格为 0.50 美元，200 日移动平均价格为 0.53 美元。该公司的市值为 37.4 亿美元，市盈率为-98.89，贝塔值为 1.38。</p>
<p>阿玛琳（NASDAQ:AMRN - 获取免费报告）最近于 3 月 12 日（星期三）发布了季度财报。这家生物制药公司报告的每股收益为（2.40 美元），低于分析师一致预期的（1.20 美元），差距为（1.20 美元）。该公司季度收入为 6231 万美元，而分析师预期为 3237 万美元。阿玛琳的股本回报率为-7.22%，净利润率为-16.33%。研究分析师预计阿玛琳公司将在本年度发布-0.15 美元的每股收益。</p>
<h2>阿玛琳的机构交易</h2>
<ul>
<li>阿玛琳在财报发布后是否值得纳入你的投资组合？</li>
</ul>
<p>几家机构投资者和对冲基金最近对该公司的持仓进行了调整。Arkfeld Wealth Strategies L.L.C.在第四季度将其在阿玛琳的持仓增加了 52.6%。Arkfeld Wealth Strategies L.L.C.现在拥有 58000 股这家生物制药公司的股票，价值 30000 美元，此前在该期间又购买了 20000 股。LCM Capital Management Inc 在第四季度将其在阿玛琳的持仓增加了 3.1%。LCM Capital Management Inc 现在拥有 838259 股这家生物制药公司的股票，价值 407000 美元，此前在上个季度又购买了 25100 股。LPL Financial LLC 在第四季度将其在阿玛琳的持仓增加了 26.0%。LPL Financial LLC 现在拥有 153020 股这家生物制药公司的股票，价值 74000 美元，此前在上个季度又购买了 31555 股。BNP Paribas Financial Markets 在第四季度将其在阿玛琳的持仓增加了 3.0%。BNP Paribas Financial Markets 现在拥有 1340920 股这家生物制药公司的股票，价值 650000 美元，此前在该期间又购买了 39452 股。最后，宾夕法尼亚州公共学校雇员退休系统在第四季度购买了阿玛琳的新股份，价值约 36000 美元。22.25% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>阿玛琳公司简介</h2>
<p>（获取免费报告）</p>
<p>阿玛琳公司是一家制药公司，专注于在美国、欧洲国家、加拿大、黎巴嫩和阿拉伯联合酋长国开发和商业化治疗心血管疾病的疗法。该公司提供 VASCEPA，这是一种处方专用的 omega-3 脂肪酸产品，用于作为饮食的辅助治疗，以降低严重高甘油三酯血症成年患者的甘油三酯水平。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票超过阿玛琳</li>
<li>股息之王宝洁在财报发布后的疲软中值得买入</li>
<li>火箭实验室股票：经受住风暴，是时候反弹了？</li>
<li>5 个适合股息增长投资者的折扣机会</li>
<li>Snowflake 通过加倍投资 AI 来推动增长</li>
<li>如何使用股票筛选器找到股票</li>
<li>IAMGOLD 股票上涨，因转型故事获得关注</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在阿玛琳吗？</h2>
<p>在你考虑阿玛琳之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而阿玛琳并不在名单上。</p>
<p>虽然阿玛琳目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

阿玛琳

<p>阿玛琳公司（NASDAQ:AMRN）在交易中达到了新的 52 周低点 0.44 美元，收盘价为 0.46 美元。分析师给予了 “卖出” 评级，市值为 37.4 亿美元，每股收益为负 2.40 美元。该公司报告的收入为 6231 万美元，超出预期。机构投资者增加了持股比例，对冲基金持有 22.25% 的股份。阿玛琳专注于心血管疾病的治疗，特别是用于降低甘油三酯水平的 VASCEPA</p>

<p>Amarin Co. plc (NASDAQ:AMRN - Get Free Report) reached a new 52-week low during trading on Friday . The stock traded as low as $0.44 and last traded at $9.11, with a volume of 1319852 shares. The stock had previously closed at $0.46.</p>
<div class="lb-trans"><p>阿玛琳公司（NASDAQ:AMRN - 获取免费报告）在周五的交易中达到了新的 52 周低点。该股最低交易价格为 0.44 美元，最后交易价格为 9.11 美元，成交量为 1319852 股。该股此前收盘价为 0.46 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><ul>
<li>3 Biotech Stocks Gaining Momentum</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只生物技术股票正在获得动力</li>
</ul>
</div><p>Separately, StockNews.com began coverage on shares of Amarin in a report on Tuesday. They issued a &#34;sell&#34; rating on the stock.</p>
<div class="lb-trans"><p>另外，StockNews.com 在周二开始对阿玛琳的股票进行覆盖。他们对该股给予了 “卖出” 评级。</p>
</div><p><strong>View Our Latest Research Report on AMRN</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 AMRN 的最新研究报告</strong></p>
</div><h2>Amarin Stock Performance</h2>
<div class="lb-trans"><h2>阿玛琳股票表现</h2>
</div><ul>
<li>Are Ocugen or Amarin Good Penny Stocks to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>Ocugen 或阿玛琳是否值得投资的便士股票？</li>
</ul>
</div><p>The firm has a 50-day moving average price of $0.50 and a two-hundred day moving average price of $0.53. The firm has a market cap of $3.74 billion, a price-to-earnings ratio of -98.89 and a beta of 1.38.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 0.50 美元，200 日移动平均价格为 0.53 美元。该公司的市值为 37.4 亿美元，市盈率为-98.89，贝塔值为 1.38。</p>
</div><p>Amarin (NASDAQ:AMRN - Get Free Report) last released its quarterly earnings data on Wednesday, March 12th. The biopharmaceutical company reported ($2.40) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by ($1.20). The company had revenue of $62.31 million for the quarter, compared to analyst estimates of $32.37 million. Amarin had a negative return on equity of 7.22% and a negative net margin of 16.33%. Research analysts anticipate that Amarin Co. plc will post -0.15 earnings per share for the current year.</p>
<div class="lb-trans"><p>阿玛琳（NASDAQ:AMRN - 获取免费报告）最近于 3 月 12 日（星期三）发布了季度财报。这家生物制药公司报告的每股收益为（2.40 美元），低于分析师一致预期的（1.20 美元），差距为（1.20 美元）。该公司季度收入为 6231 万美元，而分析师预期为 3237 万美元。阿玛琳的股本回报率为-7.22%，净利润率为-16.33%。研究分析师预计阿玛琳公司将在本年度发布-0.15 美元的每股收益。</p>
</div><h2>Institutional Trading of Amarin</h2>
<div class="lb-trans"><h2>阿玛琳的机构交易</h2>
</div><ul>
<li>Does Amarin Deserve a Spot in Your Portfolio after Earnings ?</li>
</ul>
<div class="lb-trans"><ul>
<li>阿玛琳在财报发布后是否值得纳入你的投资组合？</li>
</ul>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in the company. Arkfeld Wealth Strategies L.L.C. increased its position in Amarin by 52.6% during the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 20,000 shares during the period. LCM Capital Management Inc raised its position in Amarin by 3.1% in the 4th quarter. LCM Capital Management Inc now owns 838,259 shares of the biopharmaceutical company's stock valued at $407,000 after purchasing an additional 25,100 shares during the last quarter. LPL Financial LLC grew its position in Amarin by 26.0% during the 4th quarter. LPL Financial LLC now owns 153,020 shares of the biopharmaceutical company's stock worth $74,000 after purchasing an additional 31,555 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Amarin by 3.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,340,920 shares of the biopharmaceutical company's stock valued at $650,000 after purchasing an additional 39,452 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in shares of Amarin in the fourth quarter valued at about $36,000. 22.25% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近对该公司的持仓进行了调整。Arkfeld Wealth Strategies L.L.C.在第四季度将其在阿玛琳的持仓增加了 52.6%。Arkfeld Wealth Strategies L.L.C.现在拥有 58000 股这家生物制药公司的股票，价值 30000 美元，此前在该期间又购买了 20000 股。LCM Capital Management Inc 在第四季度将其在阿玛琳的持仓增加了 3.1%。LCM Capital Management Inc 现在拥有 838259 股这家生物制药公司的股票，价值 407000 美元，此前在上个季度又购买了 25100 股。LPL Financial LLC 在第四季度将其在阿玛琳的持仓增加了 26.0%。LPL Financial LLC 现在拥有 153020 股这家生物制药公司的股票，价值 74000 美元，此前在上个季度又购买了 31555 股。BNP Paribas Financial Markets 在第四季度将其在阿玛琳的持仓增加了 3.0%。BNP Paribas Financial Markets 现在拥有 1340920 股这家生物制药公司的股票，价值 650000 美元，此前在该期间又购买了 39452 股。最后，宾夕法尼亚州公共学校雇员退休系统在第四季度购买了阿玛琳的新股份，价值约 36000 美元。22.25% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Amarin Company Profile</h2>
<div class="lb-trans"><h2>阿玛琳公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.</p>
<div class="lb-trans"><p>阿玛琳公司是一家制药公司，专注于在美国、欧洲国家、加拿大、黎巴嫩和阿拉伯联合酋长国开发和商业化治疗心血管疾病的疗法。该公司提供 VASCEPA，这是一种处方专用的 omega-3 脂肪酸产品，用于作为饮食的辅助治疗，以降低严重高甘油三酯血症成年患者的甘油三酯水平。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Amarin</li>
<li>Dividend King Proctor &amp; Gamble Is A Buy On Post-Earnings Weakness</li>
<li>Rocket Lab Stock: Weathering the Storm, Time for a Comeback?</li>
<li>5 discounted opportunities for dividend growth investors</li>
<li>Snowflake Boosts Growth by Doubling Down on AI</li>
<li>How to Use Stock Screeners to Find Stocks</li>
<li>IAMGOLD Stock Climbs as Turnaround Story Gains Traction</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过阿玛琳</li>
<li>股息之王宝洁在财报发布后的疲软中值得买入</li>
<li>火箭实验室股票：经受住风暴，是时候反弹了？</li>
<li>5 个适合股息增长投资者的折扣机会</li>
<li>Snowflake 通过加倍投资 AI 来推动增长</li>
<li>如何使用股票筛选器找到股票</li>
<li>IAMGOLD 股票上涨，因转型故事获得关注</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amarin Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在阿玛琳吗？</h2>
</div><p>Before you consider Amarin, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑阿玛琳之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而阿玛琳并不在名单上。</p>
</div><p>While Amarin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然阿玛琳目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

阿玛琳（NASDAQ:AMRN）创下 12 个月新低 - 接下来会如何发展？